Zhu Zheng-Ming, Liu Fang-Teng, Chen Xuan
Department of General Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang, China.
The Second Clinical Medical College of Nanchang University, Nanchang, China.
Cell Physiol Biochem. 2018;46(4):1643-1649. doi: 10.1159/000489211. Epub 2018 Apr 20.
BACKGROUND/AIMS: Long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) is downregulated in various cancers and involved in both tumorigenesis and progression. The aim of this study was to assess the prognostic value of lncRNA CASC2 in cancer patients.
We searched the Web of Science, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and the Wanfang database to identify studies evaluating the prognostic value of lncRNA CASC2 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed-effects/random-effects models.
A total of eight studies were included. The combined results showed that lncRNA CASC2 was significantly associated with decreased overall survival (OS) (HR = 0.37, 95% CI, 0.27-0.46, P < 0.001). Subgroup analyses further indicated that low expression of lncRNA CASC2 predicted decreased OS in cancer patients. Additionally, low CASC2 expression levels in cancer tissues appeared to be correlated with advanced clinical staging (OR = 3.32, 95% CI, 2.29-4.80, P < 0.001).
Low CASC2 expression appears to be predictive of poor OS and advanced tumor stage in multiple cancers. CASC2 expression may serve as unfavorable prognostic factor for clinical outcomes in cancer patients.
背景/目的：长链非编码RNA（lncRNA）癌症易感性候选基因2（CASC2）在多种癌症中表达下调，并参与肿瘤发生和进展过程。本研究旨在评估lncRNA CASC2在癌症患者中的预后价值。
我们检索了Web of Science、PubMed、EMBASE、中国知网（CNKI）和万方数据库，以确定评估lncRNA CASC2在癌症患者中预后价值的研究。使用固定效应/随机效应模型计算合并风险比（HRs）或比值比（ORs）及95%置信区间（CIs）。
共纳入八项研究。综合结果显示，lncRNA CASC2与总生存期（OS）降低显著相关（HR = 0.37，95% CI：0.27 - 0.46，P < 0.001）。亚组分析进一步表明，lncRNA CASC2低表达预示癌症患者OS降低。此外，癌组织中CASC2低表达水平似乎与临床分期进展相关（OR = 3.32，95% CI：2.29 - 4.80，P < 0.001）。
CASC2低表达似乎可预测多种癌症患者的不良OS及肿瘤晚期。CASC2表达可能是癌症患者临床结局的不良预后因素。
